J&J biliary stent recall
This article was originally published in The Gray Sheet
Executive Summary
Cordis initiates Class I recall of recently revised instructions for its Precise RX biliary stent following 16 reports of adverse events and/or stent malfunctions related to off-label use in the peripheral vasculature, resulting in nine patient injuries including coma and seizure, the company reports May 7. "We regret our initial communication did not more strongly reinforce against off-label use," Dennis Donohoe, MD, Cordis VP-regulatory and clinical affairs, says in a release. The revised instructions were part of a Cordis Medical Device Notification sent to endovascular customers March 29 without FDA clearance. A May 4 follow-up notification describes the adverse events...
You may also be interested in...
Off-Label Practices Plague Circulatory System Device Randomized Trials
Off-label use of biliary stents is hindering superficial femoral artery (SFA) device development, CDRH Division of Cardiovascular Devices Director Bram Zuckerman told participants at CRT 2004 in Washington, D.C
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.